Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.

被引：1
|
作者：
Hayashi, Kaori
Mitani, Seiichiro
Taniguchi, Hiroya
Hamauchi, Satoshi
Sugiyama, Keiji
Tsushima, Takahiro
Honda, Kazunori
Todaka, Akiko
Masuishi, Toshiki
Yokota, Tomoya
Narita, Yukiya
Machida, Nozomu
Kadowaki, Shigenori
Fukutomi, Akira
Ura, Takashi
Onozawa, Yusuke
Ando, Masashi
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Shizuoka Canc Ctr Hosp, Div Med Oncol, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
    Loupakis, F.
    Cremolini, C.
    Perrone, G.
    Stasi, I.
    Salvatore, L.
    Vincenzi, B.
    Ruzzo, A.
    Ronzoni, M.
    Bencardino, K.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
    Hansen, Torben Frostrup
    Andersen, Rikke Fredslund
    Pallisgaard, Niels
    Spindler, Karen-Lise Garm
    Ploen, John
    Keldsen, Nina
    Lindebjerg, Jan
    Sorensen, Flemming Brandt
    Jakobsen, Anders
    COLORECTAL CANCER, 2014, 3 (02) : 135 - 145
  • [23] A phase I study of combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients who were previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab.
    Takahashi, Naoki
    Iwasa, Satoru
    Tachikawa, Masanori
    Fukahori, Masaru
    Sudo, Kazuki
    Sasaki, Yusuke
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko
    Takashima, Atsuo
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Shimada, Yasuhiro
    Yamagiwa, Koki
    Ebata, Yuka
    Uchida, Yasuo
    Honda, Kazufumi
    Terasaki, Tetsuya
    Yamada, Yasuhide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [24] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [25] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
    Barbosa, Caroline
    Sousa, Romulado
    Sabbaga, Jorge
    Cotti, Guilherme
    Saragiotto, Daniel
    Hoff, Paulo
    ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103
  • [26] Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS
    Hong, Yong Sang
    Kim, Hwa Jung
    Park, Seong Joon
    Kim, Kyu-Pyo
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Baek, Ji Yeon
    Kim, Sun Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (04) : 473 - 480
  • [27] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
    Caglayan Geredeli
    Nurgul Yasar
    World Journal of Surgical Oncology, 16
  • [28] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
    Geredeli, Caglayan
    Yasar, Nurgul
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [29] Cetuximab (Cmab) plus irinotecan (I) versus panitumumab (Pmab) in patients with refractory metastatic colorectal cancer (mCRC) in Ontario
    Jerzak, K. J.
    Earle, C.
    Ko, Y-J.
    Berry, S.
    Chan, K. K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
12345